| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/10/2013 | WO2013004116A1 C-3 substituted-9-deoxidized-9a-aza-9a-erythromycin a derivative |
| 01/10/2013 | WO2013004092A1 3-oxo-3, 4-dihydro-2-pyrazineformamide derivatives, pharmaceutical compositions, preparation methods and uses thereof |
| 01/10/2013 | WO2013004086A1 Fructosylated mangiferin and preparation method therefor and use thereof |
| 01/10/2013 | WO2013004075A1 Tumor targeted drug combretastatin a4 derivative |
| 01/10/2013 | WO2013004032A1 Composition for treating chicken intestine toxicity syndrome and preparation method thereof |
| 01/10/2013 | WO2013003912A1 Cryptate compounds |
| 01/10/2013 | WO2012158861A3 Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| 01/10/2013 | WO2012158776A3 Combination therapy for treatment of cancer |
| 01/10/2013 | WO2012158492A3 Treatment and management of cns disorders |
| 01/10/2013 | WO2012156999A4 Ready to use docetaxel formulation |
| 01/10/2013 | WO2012156756A3 Macrocyclic compounds as protein kinase inhibitors |
| 01/10/2013 | WO2012156537A3 Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of thrombosis and cardiovascular diseases |
| 01/10/2013 | WO2012156531A3 Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of inflammatory diseases or conditions |
| 01/10/2013 | WO2012154695A3 Treatment of polycystic disease |
| 01/10/2013 | WO2012151474A3 Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria |
| 01/10/2013 | WO2012150537A3 Novel solid forms of antibiotics |
| 01/10/2013 | WO2012149160A3 Viruses modified with unnatural moieties and methods of use thereof |
| 01/10/2013 | WO2012142476A3 Methods and compositions for the treatment of marfan syndrome and associated disorders |
| 01/10/2013 | WO2012141487A3 Cycloalkenyl aryl derivatives for cetp inhibitor |
| 01/10/2013 | WO2012134233A3 Sulphamide derivative having an adamantyl group and a pharmaceutically acceptable salt thereof |
| 01/10/2013 | WO2012134188A3 Novel oxazolidinone derivative and medical composition containing same |
| 01/10/2013 | WO2012134135A3 Spermine copolymer and gene therapy using the spermine copolymer as a nucleic-acid carrier |
| 01/10/2013 | WO2012129112A3 Use of intracellular enzymes for the release of covalently linked bioactives |
| 01/10/2013 | WO2012129057A3 Ssh-2 (slingshot-2) inhibitors and methods for making and using them |
| 01/10/2013 | WO2012126899A3 Inhibition and treatment of biofilms |
| 01/10/2013 | WO2012125872A3 Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof |
| 01/10/2013 | WO2012123493A3 Isoxazolidine derivatives |
| 01/10/2013 | WO2012121988A3 Methods for treating diseases using isoindoline compounds |
| 01/10/2013 | WO2012117073A3 New compositions for treating neurological disorders |
| 01/10/2013 | WO2012112674A3 Compounds and methods of use thereof for treating neurodegenerative disorders |
| 01/10/2013 | WO2012106722A3 Treatment of bacterial infections |
| 01/10/2013 | WO2012101065A3 Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors |
| 01/10/2013 | WO2012097223A3 Oligosaccharide conjugates for targeting bacteria and uses related thereto |
| 01/10/2013 | WO2012096832A3 Hdac inhibiting derivatives of camptothecin |
| 01/10/2013 | WO2012092484A3 Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| 01/10/2013 | WO2012075287A3 Novel selective inhibitors of prolylcarboxypeptidase |
| 01/10/2013 | WO2012069658A8 Immunomodulatory compositions comprising hydralazine for the treatment of gastrointestinal disorders |
| 01/10/2013 | WO2012061698A9 Compounds useful as modulators of trpm8 |
| 01/10/2013 | WO2012058666A3 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy |
| 01/10/2013 | WO2012054526A3 Chemosensory receptor ligand-based therapies |
| 01/10/2013 | WO2012018115A9 Composition for regenerating normal tissue from fibrotic tissue |
| 01/10/2013 | WO2011151685A8 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament |
| 01/10/2013 | WO2011131370A8 Melt-granulated fingolimod |
| 01/10/2013 | WO2011130834A8 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof |
| 01/10/2013 | WO2011117377A3 Compositions comprising brimonidine for the treatment of erythema |
| 01/10/2013 | WO2011111880A9 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 |
| 01/10/2013 | US20130013334 Methods for the identification, assessment, and treatment of patients with cancer therapy |
| 01/10/2013 | US20130012754 Microwave induced photodynamic therapy |
| 01/10/2013 | US20130012723 Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof |
| 01/10/2013 | US20130012702 Purification of progesterone receptor modulators |
| 01/10/2013 | US20130012692 Sodium channel blockers |
| 01/10/2013 | US20130012595 High alcohol content foaming compositions with silicone-based surfactants |
| 01/10/2013 | US20130012594 Method for producing astaxanthin by fermentation |
| 01/10/2013 | US20130012593 Modified release formulations of memantine oral dosage forms |
| 01/10/2013 | US20130012592 Agomelatine hydrobromide hydrate and preparation thereof |
| 01/10/2013 | US20130012591 Prophylaxis of skin cancer with retinamides |
| 01/10/2013 | US20130012590 Subcutaneous fat reduction |
| 01/10/2013 | US20130012589 Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone |
| 01/10/2013 | US20130012588 Compositions and methods for prevention and treatement of wounds |
| 01/10/2013 | US20130012587 Methods of Treating Autism |
| 01/10/2013 | US20130012586 Methods of Treating Fragile X Syndrome |
| 01/10/2013 | US20130012585 Phenylacetic Acid Derivatives |
| 01/10/2013 | US20130012584 Tranexamic Acid Formulations |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012582 Vinylic mask with peel-off effect for topical use containing high concentrations of retinoic acid |
| 01/10/2013 | US20130012581 Treatment of head lice infestations |
| 01/10/2013 | US20130012580 Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| 01/10/2013 | US20130012579 Anti-obesity Potential of Calebin A |
| 01/10/2013 | US20130012577 Process to obtain a standardized extract of quercetin and 3-o-methylquercetin from inflorescences of macela-do-campo, a cosmetic, pharmaceutical and veterinary composition containing extract of macela-do-campo, the use of this extract and the method of application of the aforesaid extract |
| 01/10/2013 | US20130012576 Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same |
| 01/10/2013 | US20130012575 Plant extract from low-thc cannabis for the treatment of disease |
| 01/10/2013 | US20130012574 Compositions and Methods for Enhanced Parvovirus Transduction |
| 01/10/2013 | US20130012572 Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
| 01/10/2013 | US20130012571 Organic Compositions to Treat Beta-ENaC-Related Diseases |
| 01/10/2013 | US20130012570 GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION |
| 01/10/2013 | US20130012569 Method of treatments related to the fmr1 gene |
| 01/10/2013 | US20130012568 Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012566 Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment of Alopecia |
| 01/10/2013 | US20130012565 4-hydroxybutyric acid analogs |
| 01/10/2013 | US20130012564 SMAC Mimetic |
| 01/10/2013 | US20130012563 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 01/10/2013 | US20130012562 Composition for Controlling Parasites on Animals |
| 01/10/2013 | US20130012561 Estrogen receptor modulators and uses thereof |
| 01/10/2013 | US20130012560 Kinesin inhibitors as cancer therapeutics |
| 01/10/2013 | US20130012559 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| 01/10/2013 | US20130012558 Use of Fungicides for the Treatment of Fish Mycoses |
| 01/10/2013 | US20130012557 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders |
| 01/10/2013 | US20130012555 Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes |
| 01/10/2013 | US20130012554 Oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, and method for treating pathogenic bacterial infections using the same |
| 01/10/2013 | US20130012553 Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors |
| 01/10/2013 | US20130012551 Method and device for producing microparticles or nanoparticles |
| 01/10/2013 | US20130012550 Methods for prognosis and monitoring cancer therapy |
| 01/10/2013 | US20130012549 Method for the Treatment, Alleviation of Symptoms of, Relieving, Improving and Preventing a Cognitive Disease, Disorder or Condition |
| 01/10/2013 | US20130012548 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 01/10/2013 | US20130012545 Amido-Thiophene Compounds and Their Use |
| 01/10/2013 | US20130012544 Pyrazolone derivatives as pde4 inhibitors |
| 01/10/2013 | US20130012543 Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| 01/10/2013 | US20130012542 Injectable depot formulation comprising crystals of iloperidone |
| 01/10/2013 | US20130012541 Therapeutic Agents Useful for Treating Pain |